China Resources Pharmaceutical Group Ltd (3320):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:China Resources Pharmaceutical Group Ltd (3320) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8280
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:59
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:香港
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
China Resources Pharmaceutical Group Ltd (CR Pharma), a subsidiary of China Resources (Holdings) Co Ltd is a pharmaceutical company that offers nutritional supplements. The company offers research and development, manufacture, and distribution of whole drug products. Its products comprise chemical medicines, TCMs, biologics, and health food and traditional Chinese medicine, and nutritional products. CR Pharma offers products in forms of oral solid dosage, large infusion bags, powder vials, oral liquid dosage, injections, and topical preparations. The company markets its products through logistics, wholesale, retail and supply chain services in different provinces across China. CR Pharma is headquartered in Hong Kong.

China Resources Pharmaceutical Group Ltd (3320) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
China Resources Pharmaceutical Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
China Resources Pharmaceutical Group Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
China Resources Pharmaceutical Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
China Resources Pharmaceutical Group Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
China Resources Pharmaceutical Group Ltd, Medical Devices Deals, 2012 to YTD 2018 11
China Resources Pharmaceutical Group Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
China Resources Pharmaceutical Group Ltd, Pharmaceuticals & Healthcare, Deal Details 15
Partnerships 15
China Resources Pharmaceutical Enters into Agreement with Fujifilm 15
China Resources Pharmaceutical Enters into Co-Development Agreement with WuXi AppTec 16
Pfizer and CR Saike Pharma Enter into Distribution Agreement 17
China Resources Zizhu Pharma Enters into Distribution Agreement with Uni-Bio Science 18
China Resources Zizhu Enters into Agreement with Uni-Bio Science 19
China Resources Pharma and National Center for Nanoscience and Technology Enter into Agreement 20
China Resources Sanjiu Medical To Form Joint Venture 21
Lantheus Medical Imaging Enters Into Co-Marketing Agreement With Beijing Double-Crane Pharma For Ultrasound Contrast Agent 22
Licensing Agreements 23
China Resources Pharma Enters into Licensing Agreement with Xbrane Biopharma 23
China Resources Pharma to Enter into Licensing Agreement with Xbrane Biopharma 24
Basilea Pharma Enters into Licensing Agreement with Shenzhen Gosun Pharma 25
Equity Offering 26
China Resources Pharma Raises USD1.8 Million in IPO 26
Debt Offering 28
China Resources Double Crane Pharma to Raise USD217.8 Million in Public Offering of Bonds 28
Acquisition 29
China Resources Double-Crane Pharma Acquires Hainan Zhonghua Union Pharma 29
China Resources Pharma Acquires 20% Stake in Hefei Tianmai Biotechnology 30
China Resources Sanjiu Medical Acquires Kunming Shenghuo Pharmaceutical 31
China Resources Sanjiu Medical Acquires China Shenghuo Pharma for USD282 Million 32
China Resources Double-Crane Pharma to Acquire 60% Stake in Jinan-based Pharmaceutical Company 33
China Resources Double Crane Pharma Acquires China Resources Saike Pharma for USD578.6 Million 34
The Special Committee Of China Shenghuo Pharma Approves Going Private Proposal From Lan’s Int’l Medicine Investment 35
China Resources Sanjiu Medical Acquires 97.18% Stake In Guilin Tianhe Pharma For US$94 Million 36
Beijing Pharma Rumored To Acquire 42% Stake In Beijing Zizhu Pharma For US$245 Million 37
Beijing Industrial Development And Beijing Zizhu To Sell 24% Stake In China Pharma For US$2 Million 38
China Resources Sanjiu Medical To Acquire Guangdong Shunfeng Pharma For US$95 Million 39
China Resources Pharmaceutical Group Ltd – Key Competitors 40
China Resources Pharmaceutical Group Ltd – Key Employees 41
China Resources Pharmaceutical Group Ltd – Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Recent Developments 44
Financial Announcements 44
Mar 21, 2018: China Resources Pharmaceutical Group: Annual Results Announcement For The Year Ended 31 December 2017 44
Aug 24, 2017: China Resources Pharmaceutical Group: Interim Results Announcement For The Six Months Ended 30 June 2017 53
Corporate Communications 57
May 21, 2018: China Resources Pharmaceutical: Change Of Non-Executive Directors And Member Of The Audit Committee 57
Aug 07, 2017: China Resources Pharmaceutical: Appointment of Independent Non-executive Director 58
Appendix 59
Methodology 59
About GlobalData 59
Contact Us 59
Disclaimer 59

List of Tables
China Resources Pharmaceutical Group Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
China Resources Pharmaceutical Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
China Resources Pharmaceutical Group Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
China Resources Pharmaceutical Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
China Resources Pharmaceutical Group Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
China Resources Pharmaceutical Group Ltd, Medical Devices Deals, 2012 to YTD 2018 11
China Resources Pharmaceutical Group Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
China Resources Pharmaceutical Enters into Agreement with Fujifilm 15
China Resources Pharmaceutical Enters into Co-Development Agreement with WuXi AppTec 16
Pfizer and CR Saike Pharma Enter into Distribution Agreement 17
China Resources Zizhu Pharma Enters into Distribution Agreement with Uni-Bio Science 18
China Resources Zizhu Enters into Agreement with Uni-Bio Science 19
China Resources Pharma and National Center for Nanoscience and Technology Enter into Agreement 20
China Resources Sanjiu Medical To Form Joint Venture 21
Lantheus Medical Imaging Enters Into Co-Marketing Agreement With Beijing Double-Crane Pharma For Ultrasound Contrast Agent 22
China Resources Pharma Enters into Licensing Agreement with Xbrane Biopharma 23
China Resources Pharma to Enter into Licensing Agreement with Xbrane Biopharma 24
Basilea Pharma Enters into Licensing Agreement with Shenzhen Gosun Pharma 25
China Resources Pharma Raises USD1.8 Million in IPO 26
China Resources Double Crane Pharma to Raise USD217.8 Million in Public Offering of Bonds 28
China Resources Double-Crane Pharma Acquires Hainan Zhonghua Union Pharma 29
China Resources Pharma Acquires 20% Stake in Hefei Tianmai Biotechnology 30
China Resources Sanjiu Medical Acquires Kunming Shenghuo Pharmaceutical 31
China Resources Sanjiu Medical Acquires China Shenghuo Pharma for USD282 Million 32
China Resources Double-Crane Pharma to Acquire 60% Stake in Jinan-based Pharmaceutical Company 33
China Resources Double Crane Pharma Acquires China Resources Saike Pharma for USD578.6 Million 34
The Special Committee Of China Shenghuo Pharma Approves Going Private Proposal From Lan's Int'l Medicine Investment 35
China Resources Sanjiu Medical Acquires 97.18% Stake In Guilin Tianhe Pharma For US$94 Million 36
Beijing Pharma Rumored To Acquire 42% Stake In Beijing Zizhu Pharma For US$245 Million 37
Beijing Industrial Development And Beijing Zizhu To Sell 24% Stake In China Pharma For US$2 Million 38
China Resources Sanjiu Medical To Acquire Guangdong Shunfeng Pharma For US$95 Million 39
China Resources Pharmaceutical Group Ltd, Key Competitors 40
China Resources Pharmaceutical Group Ltd, Key Employees 41
China Resources Pharmaceutical Group Ltd, Other Locations 42
China Resources Pharmaceutical Group Ltd, Subsidiaries 42

List of Figures
China Resources Pharmaceutical Group Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
China Resources Pharmaceutical Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
China Resources Pharmaceutical Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
China Resources Pharmaceutical Group Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
China Resources Pharmaceutical Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
China Resources Pharmaceutical Group Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
China Resources Pharmaceutical Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
China Resources Pharmaceutical Group Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
China Resources Pharmaceutical Group Ltd, Medical Devices Deals, 2012 to YTD 2018 11

★海外企業調査レポート[China Resources Pharmaceutical Group Ltd (3320):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • AgaMatrix Inc:医療機器:M&Aディール及び事業提携情報
    Summary AgaMatrix Inc (AgaMatrix) is a medical device company that offers biosensors and blood glucose monitors. The company designs, develops and manufactures diabetes products for pharmaceutical companies. Its products comprise Jazz Wireless 2, blood glucose monitors, Connected Health and AgaMatri …
  • Australian Vanadium Ltd (YRR):企業の財務・戦略的SWOT分析
    Summary Australian Vanadium Ltd (AVL), formerly Yellow Rock Resources Ltd, is a mining company that explores and develops titanium, vanadium, copper, gold, and uranium metals. The company’s projects include Gabanintha Gold Copper Project, The Australian Vanadium Project, Coates Vanadium Project, Now …
  • Modern Times Group MTG AB:企業の戦略・SWOT・財務分析
    Modern Times Group MTG AB - Strategy, SWOT and Corporate Finance Report Summary Modern Times Group MTG AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Alfresa Holdings Corporation:企業の戦略・SWOT・財務情報
    Alfresa Holdings Corporation - Strategy, SWOT and Corporate Finance Report Summary Alfresa Holdings Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • BEML Ltd:企業の戦略・SWOT・財務分析
    BEML Ltd - Strategy, SWOT and Corporate Finance Report Summary BEML Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Parsons Corporation:企業の戦略・SWOT・財務分析
    Parsons Corporation - Strategy, SWOT and Corporate Finance Report Summary Parsons Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Dartmouth College-製薬・医療分野:企業M&A・提携分析
    Summary Dartmouth College (Dartmouth) is an academic and research institute that offers undergraduate and graduate educational programs. The institute offers programs in the fields of arts, sciences, business administration, medicine, and engineering. It operates through various faculties such as th …
  • ImmunoGen Inc (IMGN):企業の財務・戦略的SWOT分析
    ImmunoGen Inc (IMGN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Olympus Corporation:企業の戦略・SWOT・財務分析
    Olympus Corporation - Strategy, SWOT and Corporate Finance Report Summary Olympus Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Central Japan Railway Co (9022):企業の財務・戦略的SWOT分析
    Central Japan Railway Co (9022) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • BARMER GEK:企業の戦略的SWOT分析
    BARMER GEK - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Severstal:企業の戦略・SWOT・財務情報
    Severstal - Strategy, SWOT and Corporate Finance Report Summary Severstal - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Itochu Chemical Frontier Corp:製薬・医療:M&Aディール及び事業提携情報
    Summary Itochu Chemical Frontier Corp (ICF), formerly Ando Kaseihin KK, a subsidiary of Itochu Corporation, is a chemical company that manufactures and markets chemical products. The company’s business division includes intermediate chemical division, performance product division, eco chemical and l …
  • Hooper Holmes Inc (HH)-製薬・医療分野:企業M&A・提携分析
    Summary Hooper Holmes Inc (Hooper Holmes) is a provider of health and screening services. The company provides health services such as individual screenings at home or work, onsite screenings for small and large companies, remote screenings for individuals and eligible family members, convenient wal …
  • NetSol Technologies, Inc. (NTWK):企業の財務・戦略的SWOT分析
    NetSol Technologies, Inc. (NTWK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Hudson’s Bay Company:企業の戦略・SWOT・財務情報
    Hudson's Bay Company - Strategy, SWOT and Corporate Finance Report Summary Hudson's Bay Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Intelsat S.A. (I):企業の財務・戦略的SWOT分析
    Intelsat S.A. (I) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Dong-A Socio Holdings Co Ltd (000640):企業の財務・戦略的SWOT分析
    Dong-A Socio Holdings Co Ltd (000640) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • ATS Automation Tooling Systems Inc (ATA):企業の財務・戦略的SWOT分析
    ATS Automation Tooling Systems Inc (ATA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Barclaycard:企業の戦略・SWOT・財務分析
    Barclaycard - Strategy, SWOT and Corporate Finance Report Summary Barclaycard - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆